RESUMO
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a rare and early-onset neurodegenerative disease caused by variants of the SACS gene which maps to chromosome 13q11 and encodes sacsin protein. Sacsin is highly expressed in large motor neurons, in particular cerebellar Purkinje cells. This article has provided a review for the structure and function of sacsin protein and the mechanisms underlying abnormalities of sacsin in ARSACS disease.
Assuntos
Humanos , Ataxias Espinocerebelares/patologia , Ataxia/genética , Espasticidade Muscular/genéticaRESUMO
Objective: To explore the clinical manifestations and genetic characteristics of patients with epilepsy and episodic ataxia caused by SCN2A gene variation. Methods: The clinical data of seizure manifestation, imaging examination and genetic results of 5 patients with epilepsy and (or) episodic ataxia because of SCN2A gene variation admitted to the Department of Pediatrics, the Third Affiliated Hospital of Zhengzhou University from July 2017 to January 2021 were analyzed retrospectively. Results: Among 5 patients, 4 were female and 1 was male. The onset age of epilepsy ranged from 4 days to 8 months. There were 2 cases of benign neonatal or infantile epilepsy and 3 cases of epileptic encephalopathy, in whom 1 case had development retardation,1 case transformed from West syndrome to infantile spasm and another one transformed from infantile spasm to Lennox-Gastaut syndrome. One case of benign neonatal-infantile epilepsy was characterized by neonatal onset seizures and episodic ataxia developed at the age of 78 months. Electroencephalograms at first visit of 5 cases showed that 2 cases were normal, 1 case had focal epileptic discharge, and 2 cases had multi-focal abnormal discharge with peak arrhythmia. The brain magnetic resonance imaging (MRI) of 3 cases were nomal, 1 case was abnormal (brain atrophy with decreased white matter) and the results of 1 case was unknown. The follow-up time ranged from 17 months to 89 months. Four cases of epilepsy were controlled and 1 case died at 2 years of age. Two cases had normal intelligence and motor development, 2 had moderate to severe intelligence retardation and motor critical state, and 1 had moderate to severe intelligence and motor development retardation. SCN2A gene variations were identified in all cases. There were 4 missense variations and 1 frameshift variation. Three variations had not been reported so far, including c.4906A>G,c.3643G>T,c.638delT. Conclusions: Variations in SCN2A gene can cause benign neonatal or infantile epilepsy and epileptic encephalopathy. Some children develop episodic ataxia with growing age. The variation of SCN2A gene is mainly missense variation.
Assuntos
Criança , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Ataxia/genética , Eletroencefalografia , Epilepsia/genética , Mutação , /genética , Estudos Retrospectivos , Espasmos Infantis/genéticaRESUMO
OBJECTIVE@#To explore the genetic basis for a child with myopathy and cerebellar atrophy with ataxia.@*METHODS@#Clinical examinations and laboratory testing were carried out for the patient. The proband and the parents' genomic DNA was extracted from peripheral blood samples and subjected to trio whole-exome sequencing. Candidate variant was validated by Sanger sequencing.@*RESULTS@#The 1-year-and-8-month-old boy manifested motor developmental delay, ataxia, hypomyotonia, increased serum creatine kinase. Cranial MRI showed cerebellar atrophy with progressive aggravation. Genetic testing revealed that the patient has harbored compound heterozygous variants of the MSTO1 gene, namely c.13delG (p.Ala5ProfsTer68) and c.971C>T (p.Thr324Ile), which were respectively inherited from his mother and father. The former was unreported previously and was predicted to be likely pathogenic, whilst the latter has been reported previously and was predicted to be of uncertain significance.@*CONCLUSION@#The compound heterozygous c.13delG (p.Ala5ProfsTer68) and c.971C>T (p.Thr324Ile) variants probably underlay the disease in the proband. Above finding has enriched the spectrum of MSTO1 gene variants underlying mitochondrial myopathy and cerebellar atrophy with ataxia.
Assuntos
Criança , Humanos , Lactente , Masculino , Ataxia/genética , Atrofia/genética , Proteínas de Ciclo Celular/genética , Proteínas do Citoesqueleto/genética , Miopatias Mitocondriais , Mutação , Doenças Neurodegenerativas , Sequenciamento do ExomaRESUMO
Abstract Introduction: The FMR1 gene has four allelic variants according to the number of repeats of the CGG triplet. Premutation carriers with between 55 and 200 repeats are susceptible to developing pathologies such as tremor and ataxia syndrome (FXTAS) and fragile X-associated primary ovarian insufficiency (FXPOI) syndrome. Case description: The patient was a 53-year-old female farmer with severe tremor in the upper limbs at rest that worsens with movement, tremor in the jaw and tongue, and generalized cerebral atrophy. She is a carrier of the FMR1 premutation diagnosed by PCR and Southern Blot, complying with the clinical and radiological criteria of FXTAS, and in addition, has a history of vagal symptoms suggestive of ovarian failure and menstrual cycle disorders that led to hysterectomy at age 33 and was subsequently diagnosed with FXPOI. Conclusion: An unusual case of FXTAS and FXPOI complying with clinical and radiological criteria is reported in a premutation carrier of the FMR1 gene.
Resumen Introducción: el gen FMR1 tiene cuatro variantes alélicas según el número de repeticiones de la tripleta CGG. Los portadores de la premutación con un número entre 55 y 200 repeticiones son susceptibles de desarrollar patologías como el síndrome de temblor y ataxia (FXTAS) y síndrome de falla ovárica prematura (FXPOI) asociados al X frágil. Descripción del caso: Mujer de 53 años, agricultora, con temblor severo en miembros superiores en reposo que empeora con el movimiento, temblor en mandíbula y lengua, atrofia cerebral generalizada, portadora de la premutación del gen FMR1 diagnosticada por PCR y Southern Blot, cumpliendo con criterios clínicos y radiológicos de FXTAS; ademas, historia de síntomas vagales sugestivos de falla ovárica y trastornos del ciclo menstrual que llevaron a histerectomía a los 33 años, haciendose diagnóstico FXPOI. Conclusión: Se reporta un caso inusual en portadoras de la premutación del gen FMR1, con criterios clínicos y radiológicos de FXTAS y FXPOI.
Assuntos
Feminino , Humanos , Pessoa de Meia-Idade , Ataxia/genética , Tremor/genética , Insuficiência Ovariana Primária/genética , Proteína do X Frágil da Deficiência Intelectual/genética , Síndrome do Cromossomo X Frágil/genética , Southern Blotting , Reação em Cadeia da Polimerase , Repetições de Trinucleotídeos/genética , AlelosRESUMO
BACKGROUND: Coenzyme Q10 (CoQ10 or ubiquinone) deficiency can be due either to mutations in genes involved in CoQ10 biosynthesis pathway, or to mutations in genes unrelated to CoQ10 biosynthesis. CoQ10 defect is the only oxidative phosphorylation disorder that can be clinically improved after oral CoQ10 supplementation. Thus, early diagnosis, first evoked by mitochondrial respiratory chain (MRC) spectrophotometric analysis, then confirmed by direct measurement of CoQ10 levels, is of critical importance to prevent irreversible damage in organs such as the kidney and the central nervous system. It is widely reported that CoQ10 deficient patients present decreased quinone-dependent activities (segments I + III or G3P + III and II + III) while MRC activities of complexes I, II, III, IV and V are normal. We previously suggested that CoQ10 defect may be associated with a deficiency of CoQ10-independent MRC complexes. The aim of this study was to verify this hypothesis in order to improve the diagnosis of this disease. RESULTS: To determine whether CoQ10 defect could be associated with MRC deficiency, we quantified CoQ10 by LC-MSMS in a cohort of 18 patients presenting CoQ10-dependent deficiency associated with MRC defect. We found decreased levels of CoQ10 in eight patients out of 18 (45 %), thus confirming CoQ10 disease. CONCLUSIONS: Our study shows that CoQ10 defect can be associated with MRC deficiency. This could be of major importance in clinical practice for the diagnosis of a disease that can be improved by CoQ10 supplementation.
Assuntos
Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Ataxia/genética , Transporte de Elétrons/genética , Mutação , Doenças Mitocondriais/genética , Debilidade Muscular/genética , Ubiquinona/análogos & derivados , Ubiquinona/deficiência , Ataxia/diagnóstico , Ataxia/metabolismo , Biópsia , Células Cultivadas , Cromatografia Líquida , Fibroblastos/enzimologia , Doenças Mitocondriais/diagnóstico , Doenças Mitocondriais/metabolismo , Debilidade Muscular/diagnóstico , Debilidade Muscular/metabolismo , Músculos/patologia , Espectrofotometria/métodos , Espectrometria de Massas em Tandem/métodos , Ubiquinona/biossíntese , Ubiquinona/genética , Ubiquinona/metabolismoRESUMO
Chronic ataxias are an heterogeneous group of disorders that affect the child at different ages. Thus, the congenital forms, generally non progressive are observed from first months of life and are expressed by hypotonia and motor delay long before the ataxia became evident. The cerebral magnetic resonance images (MRI) may be diagnostic in some pictures like Joubert syndrome. The group of progressive hereditary ataxias, usually begin after the infant period. The clinical signs are gait instability and ocular apraxia that can be associated with oculocutaneous telangiectasias (ataxia-telangiesctasia) or with sensory neuropathy (Friedreich ataxia). In this review are briefly described congenital ataxias and in more detailed form the progressive hereditary ataxias autosomal recessive, autosomal dominants and mitochondrials. The importance of genetic study is emphasized, because it is the key to obtain the diagnosis in the majority of these diseases. Although now there are no treatments for the majority of progressive hereditary ataxias, some they have like Refsum disease, vitamine E deficiency, Coenzyme Q10 deficiency and others, thus the diagnosis in these cases is even more important. At present the diagnosis of childhood hereditary ataxia not yet treatable is fundamental to obtain suitable handling, determine a precise outcome and to give to the family an opportune genetic counseling.
Assuntos
Ataxia Cerebelar/genética , Degenerações Espinocerebelares/genética , Ataxia Cerebelar/diagnóstico , Ataxia Cerebelar/fisiopatologia , Ataxia/diagnóstico , Ataxia/fisiopatologia , Ataxia/genética , Criança , Debilidade Muscular/diagnóstico , Debilidade Muscular/fisiopatologia , Debilidade Muscular/genética , Degenerações Espinocerebelares/diagnóstico , Degenerações Espinocerebelares/fisiopatologia , Doença Crônica , Doenças Mitocondriais/diagnóstico , Doenças Mitocondriais/fisiopatologia , Doenças Mitocondriais/genética , Feminino , Humanos , Masculino , Ubiquinona/deficiência , Ubiquinona/genéticaRESUMO
FXTAS (Fragile X-associated tremor and ataxia syndrome) is a late- onset neurodegenerative disorder affecting mainly men, over 50 years of age, who are carriers of the FMR1 gene premutation. The full mutation of this gene causes the fragile X syndrome (FXS), the most common cause of inherited mental retardation. Individuals affected by FXTAS generally present intention tremor and gait ataxia that might be associated to specific radiological and/or neuropathological signs. Other features commonly observed are parkinsonism, cognitive decline, peripheral neuropathy and autonomic dysfunction. Nearly a decade after its clinical characterization, FXTAS is poorly recognized in Brazil. Here we present a review of the current knowledge on the clinical, genetic and diagnostic aspects of the disease.
A FXTAS (síndrome de tremor e ataxia associada ao X frágil) é uma doença neurodegenerativa de início tardio que afeta principalmente homens acima dos 50 anos de idade, portadores de pré-mutação do gene FMR1. A mutação completa desse gene é responsável pela síndrome do cromossomo X frágil (SXF), a causa mais comum de deficiência mental herdada. Indivíduos afetados pela FXTAS geralmente apresentam tremor de intenção e ataxia de marcha que podem estar associados a sinais radiológicos ou neuropatológicos específicos. Outras características comumente observadas são parkinsonismo, declínio cognitivo, neuropatia periférica e disfunções autonômicas. Quase uma década após sua caracterização clínica, a FXTAS é mal conhecida por médicos no Brasil. Esta revisão apresenta o conhecimento atual sobre os aspectos clínicos, genéticos e diagnósticos da síndrome.
Assuntos
Animais , Humanos , Masculino , Pessoa de Meia-Idade , Ataxia , Síndrome do Cromossomo X Frágil , Proteína do X Frágil da Deficiência Intelectual/genética , Tremor , Ataxia/diagnóstico , Ataxia/tratamento farmacológico , Ataxia/genética , Síndrome do Cromossomo X Frágil/diagnóstico , Síndrome do Cromossomo X Frágil/tratamento farmacológico , Síndrome do Cromossomo X Frágil/genética , Imageamento por Ressonância Magnética , Tremor/diagnóstico , Tremor/tratamento farmacológico , Tremor/genéticaRESUMO
Joubert syndrome is a very rare autosomal recessive disorder with only 200 cases reported worldwide.Here we report 4 cases of this rare disorder with MRI findings.
Assuntos
Ataxia/complicações , Ataxia/genética , Cerebelo/anormalidades , Pré-Escolar , Transtornos Cromossômicos/genética , Deficiências do Desenvolvimento/complicações , Deficiências do Desenvolvimento/genética , Humanos , Lactente , Deficiência Intelectual/complicações , Deficiência Intelectual/genética , Imageamento por Ressonância Magnética , Masculino , Hipotonia Muscular/complicações , Hipotonia Muscular/genética , Doenças do Nervo Oculomotor/complicações , Doenças do Nervo Oculomotor/genética , Transtornos Respiratórios/complicações , Transtornos Respiratórios/genética , SíndromeRESUMO
A late onset neurological syndrome in carriers of premutation in FMR1 gene was recently described. The condition was named fragile-X-associated tremor/ataxia syndrome (FXTAS) and includes intentional tremor, cerebellar ataxia, parkinsonism, and cognitive deficit. We ascertained the contribution of FMR1 premutation to the phenotypes ataxia, tremor and/or parkinsonism. Sixty-six men over 45 years old presenting these symptoms, isolated or combined, were tested. Also, 74 normal men, randomly chosen in the population, formed the control group. In the patient group, no premutation carrier was found, which is in agreement with other observed frequencies reported elsewhere (0-5% variation). No significant differences were found when comparing gray zone allele frequencies among target and control groups. The FXTAS contribution in patients with phenotypic manifestations of FXTAS was 15/748 (2%). The presence of gray zone alleles is not correlated with FXTAS occurrence.
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Ataxia/diagnóstico , Doença de Parkinson/diagnóstico , Frequência do Gene , Proteína do X Frágil da Deficiência Intelectual/genética , Tremor/diagnóstico , Alelos , Ataxia/fisiopatologia , Ataxia/genética , Ataxia/patologia , Estudos de Casos e Controles , Doença de Parkinson/fisiopatologia , Doença de Parkinson/genética , Doença de Parkinson/patologia , Predisposição Genética para Doença , Tremor/fisiopatologia , Tremor/genética , Tremor/patologiaRESUMO
Se describe una hermandad de 2 individuos quienes fueron atendidos en nuestra consulta por presenatr un cuadro de ataxia y atrofia óptica bilateral asociada a signos piramidales. Las primeras manifestaciones clínicas comenzaron alrededor del año de edad y siguieron un curso lentamente progresivo. Los casos fueron diagnosticados como afectados del Síndrome de Behr, de etiología autosómica recesiva. Se destacan las características del síndrome y se realiza un revisión bibliográfica respecto a esta muy rara entidad aún no reportada en nuestro país
Assuntos
Criança , Humanos , Masculino , Feminino , Atrofia Óptica/genética , Ataxia/genéticaRESUMO
Presentamos una familia con un cuadro de ataxia hereditaria paroxística trasmitida en forma autosómica dominante. Los episodios se caracterizaron por ataques de severa ataxia y vértigo. Los ataques ocurrían tres veces por semana. No había trastornos de conciencia, pero durante las crisis el vértigo hace la deambulación imposible. Entre los ataques los pacientes presentaron exámenes neurológicos normales. La acetazolamida (250-500 mg/día) suprimió prácticamente los ataques. La dramática respuesta a esta terapéutica hace necesario el diagnóstico de este cuadro que tal vez sea más frecuente de lo que se piensa actualmente